Abstract Library

#4237 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

Introduction: Advanced gastroenteropancreatic neuroendocrine tumors (GEP NET) are treated with targeted therapy or peptide receptor radionuclide therapy (PRRT) (177Lu-DOTATATE) upon progression under somatostatin analogues (SSA). SSA are continued life-long in functional NET, but the benefit of SSA continuation in non-functional NET is unclear. Due to ongoing activity of the somatostatin receptor pathway in GEP NET progressing on SSA, we hypothesize an added efficacy of SSA during second-line therapy.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Kuiper J, Borbath I, Dercksen W, Deroose C,

Keywords: somatostatin analogues, SSA, everolimus, sunitinib, peptide receptor radionuclide therapy, PRRT, quality of life, QoL, gastroenteropancreatic neuroendocrine tumor, GEP NET,

#4144 Phase Ib portion of the ACTION-1 Phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings

Introduction: RYZ101 (225Ac-DOTATATE) is an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors.

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Ulaner G, Halperin D, Mehr S, Kotiah S,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Somatostatin analogue therapy, Somatostatin receptor positive, RYZ101,

#4091 Grade 2 (G2) gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs): Risk stratification beyond Ki-67?

Introduction: G2 GEP-NETs are well-differentiated neuroendocrine neoplasms with Ki-67 proliferation index of 3-20%. Rather than behaving as a monolithic category, these neoplasms are often characterized by an unpredictable outcome, and additional biomarkers are needed.

Conference:

Presenting Author:

Authors: Laffi A, Zerbi A, Lavezzi E, Carrara S, Rossi E,

Keywords: GEP NET, G2, neuroendocrine tumor, neuroendocrine,

#4042 177Lu-dotatate as salvage therapy in bronchial and GEP NET patients: The IRST "Dino Amadori" experience

Introduction: RLT with SSA represents a treatment of choice after progression from “cold” SSA analogues in NENs. After progression from RLT, other systemic treatments are used including a salvage therapy with RLT that is increasingly proposed.

Conference:

Presenting Author:

Authors: Sansovini M,

Keywords: Neuroendocrine tumor, salvage radioligand therapy,

#3823 Added value of post 177Lu Dotatate and Ga PET/CT imaging in prediction and evaluation of treatment response for GEP NETs

Introduction: Theragnostic approach using 68Ga Dota-peptides (PET) for diagnosis and Lutetium-177 Dotatate (Lutate) for therapy is approved in gastroenteropancreatic neuroendocrine tumors (GEP-NET). The 24-hour post-Lutate treatment imaging (Lutate post tp) evaluates the radiotracer distribution.

Conference:

Presenting Author: Abenavoli E

Authors: Abenavoli E, Linguanti F, Briganti V, Antonuzzo L, Mungai F,

Keywords: Lutetium-177 Dotatate, 68Ga-Dota peptide, evaluation response, prediction response, imaging parameter,